BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
Condition: Neoplasms Interventions: Drug: Encorafenib; Drug: Cetuximab; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Capecitabine; Drug: Bevacizumab Sponsors: Pfizer; Ono Pharmaceutical Co. Ltd; Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Erbitux | Germany Health | Pfizer | Research | Study | Xeloda